Anavex Life Sciences receives US patent for ANAVEX 2-73 (blarcamesine)
Anavex Life Sciences has secured new US intellectual property compositions patent for its ANAVEX 2-73 (blarcamesine). The patent number 11,661,405 has …
Swiss company Lonza acquires Synaffix to boost ADC offering
Switzerland-based company Lonza has boosted its antibody-drug conjugates (ADCs) offering with the acquisition of Dutch biotechnology company Synaffix for a …
Rentschler Biopharma and Ikarovec partner to expedite new gene therapies
Rentschler Biopharma has collaborated with Ikarovec for expediting the new gene therapies to treat ophthalmic disease. Under the deal, Rentschler Biopharma’s …
China’s NMPA approves Vascepa for hypertriglyceridemia
China’s National Medical Products Administration (NMPA) has granted regulatory approval to Amarin’s commercial partner EddingPharm (EDDING) for Vascepa (icosapent ethyl). Vascepa …
Sanofi’s frexalimab shows early potential in in Phase II multiple sclerosis trial
Sanofi has announced that its anti-CD40L antibody frexalimab demonstrated significantly reduced disease activity in a Phase II trial of patients …
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
AstraZeneca and MSD’s Lynparza combo bags FDA approval for prostate cancer
The US Food and Drug Administration (FDA) has granted a combination of AstraZeneca and MSD’s Lynparza (olaparib), with standard therapies …
Pneumagen raises £8 million for further study of intranasal antiviral
Pneumagen has raised £8m ($10 million) for the further development of its intranasal antiviral drug neumifil in Phase II studies …
InDex Pharmaceuticals signs licence deal with Viatris for cobitolimod
InDex Pharmaceuticals has entered a licence deal with Viatris Pharmaceutical Japan for the development and commercialisation of cobitolimod in Japan …
Algernon announces acceptance of Repirinast patent application in Japan
Algernon Pharmaceuticals’ patent application for NP-251 (Repirinast) has been accepted by the Japanese Patent Office (JPO) for the treatment of …
Negative FDA AdCom vote for Intercept’s obeticholic acid in NASH
On 19 May, the FDA’s Gastrointestinal Drugs Advisory Committee (GDAC), by a vote of 12 to two, with two abstentions, …
UK’s NICE recommends Pfizer’s rimegepant to treat migraine
The UK’s National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending the use of Pfizer’s …
USPTO grants Notice of Allowance for Tenax Therapeutics’ oral levosimendan
The US Patent and Trademark Office (USPTO) has granted a Notice of Allowance for Tenax Therapeutics’ patent application covering its …
New UK intracellular drug delivery centre to support RNA development
A new intracellular drug delivery centre will be established in the UK to support potential ribonucleic acid (RNA) vaccines and …
FDA approves Analog and Dipharma’s ANDA for nitisinone capsules
The US Food and Drug Administration (FDA) has granted clearance to Analog Pharma and Dipharma’s abbreviated new drug application (ANDA) …
(Cilnidipine + tadalafil) by AISA Pharma for Raynauds Disease: Likelihood of Approval
(Cilnidipine + tadalafil) is under clinical development by AISA Pharma and currently in Phase II for Raynauds Disease. According to …